$INSM

Insmed (NASDAQ: INSM) holder Padonia targets $638K share sale

Padonia LLC, linked to Melvin Sharoky, filed a Form 144 notice for a proposed sale of up to 5,000 shares of Insmed Inc. common stock (NASDAQ: INSM). The filing cites an approximate aggregate market value of $637,636.84 and references a prior open-market purchase of 10,000 shares on May 15, 2023.

Original reporting
Published Aug 17, 2026, 8:19 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 18, 2026, 5:41 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefFinancial news
Primary signal
$INSM
Bearish
medium confidence
Mentioned
$INSM
Relevance
4/10
alphai data visualization · based on stocktitan.net
Decision brief

The 30-second read

$INSMBearishLow
01

Why it matters

Traders may monitor INSM for incremental selling pressure if the holder proceeds with sales, but the disclosed quantity suggests limited supply impact.

02

Market read

A proposed sale of up to 5,000 INSM shares is disclosed via Form 144, which can modestly pressure sentiment but is unlikely to be a major driver by itself.

03

What to watch

The notice does not specify sale dates, execution venue, or whether the shares are already freely tradable; actual market impact depends on subsequent trades.

Relevance 4/10Novelty 4/10Timing: Form 144 notice filed for a proposed sale, reported after-hours on 2026-08-17.

Background

The article summarizes a Form 144 notice, which is filed when holders plan potential resales of restricted or control securities under SEC rules.

Company-level read

Ticker impact

$INSMBearishMedium confidence
Context

Padonia LLC filed a Form 144 to sell up to 5,000 Insmed shares, citing an approximate aggregate market value of $637,636.84.

Expected impact

Likely limited immediate impact; any effect would be sentiment-driven rather than fundamental.

Evidence & confidence

Form 144 signals intent to sell restricted/control securities, but the notice covers only 5,000 shares (about $0.64M) and provides no execution timing or price.

Market effects

Minimal sector read-through; this is a single-holder selling notice with small disclosed size.

No clear regional spillover beyond US small-cap biotech sentiment.

No global relevance indicated.

Counterpoint

The Form 144 may be routine compliance for potential sales and does not confirm that shares will actually be sold soon or at all.

Key entities

  • Insmed Inc.

    NASDAQ-listed company whose common stock is covered by the Form 144 notice.

  • Padonia LLC

    Reporting holder associated with Melvin Sharoky, filing the Form 144 for a proposed sale.

  • Melvin Sharoky

    Associated with Padonia LLC, referenced in the filing summary.

Related articles

$INSMHighAI 8/10

Insmed’s (INSM) New Drug Launch Is Reshaping The Whole Business

Insmed (INSM) reported Q2 2026 revenue of $425.5M, up 296% YoY, with net loss narrowing to $13.2M. BRINSUPRI sales reached $309.2M, up 49% QoQ. The company raised full-year BRINSUPRI guidance to $1.25B-$1.40B. Insmed also increased its peak revenue estimate for lead programs to over $14B. Expenses rose due to commercial buildout and R&D spending.

$INSMMedAI 8/10

Is Insmed (INSM) Undervalued Following Japan Approval For BRINSUPRI?

Insmed (INSM) received approval for BRINSUPRI in Japan, adding to U.S. and European clearances. Shares rose 2.78% to $121.84, with a 30-day return of 23.57% but a YTD decline of 31.21%. Analysts suggest a fair value of $197.14, indicating potential undervaluation, but risks include approval delays and reimbursement challenges.

$GILDMedAI 8/10

Weekly Buzz: Gilead Sciences, Roivant Sciences Win FDA Nod; Biohaven, Eli Lilly Strike Deal; Spyre Therapeutics Misses Monotherapy Goal

Gilead (GILD) and Roivant (ROIV) received FDA approvals for Bixlenvo and LISRAYA, respectively. Johnson & Johnson (JNJ) also gained approval for IMAAVY. Biohaven (BHVN) and Eli Lilly (LLY) advanced partnerships. Spyre Therapeutics missed a clinical trial goal. Key stocks: GILD +0.52%, ROIV +2.26%, JNJ -1.57%.

$INSMHighAI 9/10

BRINSUPRI® (brensocatib) Approved by Japan's Ministry of Health, Labour and Welfare for the Treatment of Patients With Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease

Insmed Inc. (INSM) announced Japan's approval of BRINSUPRI® (brensocatib) for treating non-cystic fibrosis bronchiectasis (NCFB) in adults and pediatric patients 12+. The approval is based on Phase 3 ASPEN study results showing reduced pulmonary exacerbations and lower lung function decline. BRINSUPRI is now approved in the U.S., Europe, and Japan.

$INSMMed

How Insmed’s Sharply Narrowed Q2 2026 Net Loss At Insmed (INSM) Has Changed Its Investment Story

Insmed Inc. (INSM) reported a sharply narrowed net loss of $13.24M in Q2 2026, down from $321.69M a year earlier, with loss per share at $0.06 vs. $1.70. The company's H1 2026 net loss also improved to $176.81M from $578.27M, indicating lower cash burn. Insmed's investment narrative focuses on its respiratory portfolio, particularly brensocatib, with guidance projecting $1B in 2026 BRINSUPRI revenue and $450M-$470M from ARIKAYCE. The company aims for $4.1B revenue and $1B earnings by 2029, requi